Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention

Annals of Pharmacotherapy

Volumn 39, Issue 10, 2005, Pages 1621-1626

  Coons, James C ^a,b   Seybert, Amy L ^c   Saul, Melissa I ^d   Kirisci, Levent ^c   Kane Gill, Sandra L ^c,e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e Center for Pharmacoinformatics and Outcomes Research   (United States)

Author keywords

Abciximab; Eptifibatide; Percutaneous coronary intervention; Stent

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; BLEEDING; COHORT ANALYSIS; CORONARY STENT; DEATH; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COHORT STUDIES; DRUG COSTS; FEMALE; FIBRINOLYTIC AGENTS; HOSPITAL COSTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PEPTIDES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 25844441642     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G129     Document Type: Article

References (23)

1. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-35.
2. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA 1999;281:1407-14.
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigators. N Engl J Med 1994;330:956-61.
4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
5. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35. Erratum 1997;350:744
6. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
7. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338:1498-505.
8. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-97.
9. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-53.
10. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-8.
11. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
12. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-44.
13. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al., for the TARGET Investigators. Do tirofiban and Reopro give similar efficacy trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-94.
14. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2002;40:1366-74.
15. Kimmelstiel C, Phang R, Rehman A, Rand W, Miele R, Rhofiry J, et al. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention. J Thromb Thrombolysis 2001;11:203-9.
16. Suleiman M, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J Invasive Cardiol 2003;15:319-23.
17. McCollam PL, Foster DA, Riesmeyer JS. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Health Syst Pharm 2003;60:1251-6.
18. Koneti AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
19. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators. N Engl J Med 1993;329:673-82.
20. Williams BA, Kentor ML, Vogt MT, Coley KC, Williams JP, Roberts MS, et al. Economics of nerve block pain management after anterior cruciate ligament reconstruction. Anesthesiology 2004;100:697-706.
21. Levey AS, Greene T, Kusek JW, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000;11:A0828.
22. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary inter-vention: Prairie Reopro Versus Integrilin Cost Evaluation (PRICE) Trial. Am Heart J 2001;141:402-9.
23. Brown DL, Fann CSJ, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87:537-41.